医药行业周报：艾伯维IL-23抑制剂再获FDA批准，治疗溃疡性结肠炎

Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as Neutral [1][2]. Core Insights - The report maintains a positive outlook on the pharmaceutical sector, highlighting the recent FDA approval of AbbVie’s IL-23 inhibitor for treating ulcerative colitis, which is expected to enhance market sentiment [2][4]. - The pharmaceutical sector experienced a decline of 1.19% on June 19, 2024, underperforming the CSI 300 index by 0.71 percentage points, ranking 22nd among 31 sub-industries [4]. - Notable stock performances include a 20% increase for Lixun Medical and a 9.41% decrease for Baotai [4]. Summary by Sections Industry Ratings - The pharmaceutical industry is rated as Neutral, indicating expected returns between -5% and 5% relative to the CSI 300 index over the next six months [7]. Company News - Notable company announcements include: - Northeast Bio expects a net profit of 180-250 million yuan for the first half of 2024, a year-on-year increase of 330.08% to 497.34% [5]. - Jichuan Pharmaceutical received approval for a new drug, a second-generation H1 receptor antagonist [5]. - Dizhe Pharmaceutical announced the approval of a new drug for treating relapsed or refractory peripheral T-cell lymphoma [5]. - Xinhua Pharmaceutical received approval for pregabalin capsules, used for treating postherpetic neuralgia [5].